7/23/24 – Erica successfully defended her thesis.
Shelby Fertal achieves a fundable score on her F31 proposal
Nov 2023 – Congratulations to Shelby Fertal on her 12th percentile F31 score!
Erica Hoffman presents at the 2023 Midwest TME Meeting
May 2023 – Erica Hoffman is selected for an oral presentation at the 2023 Midwest TME meeting at Purdue University.
Ponik Lab student presents data at the Undergraduate Research Symposium
May 2023 – Nour Munzer Haidar presents her Bio152 research project investigating how breast cancer risk factors (obesity and breast density) impact inflammatory signaling in normal mammary glands.
Congratulations to Metti Gari!
August 2022 – Ponik lab graduate student, Metti Gari, successfully completed her preliminary exam, “PEG-FUD as an anti-cancer therapy for breast cancer”. She is now a dissertation in the Molecular and Cellular Pharmacology Program at …
The Ponik and Kwon labs collaborate to improve the tumor targeting potential of an anti-fibrotic inhibitor of fibronectin assembly.
August 2022. In this study we demonstrated improved tumor targeting and biodistribution of 20-kDa PEG conjugated FUD peptide (PEG-FUD) in the 4T1 murine breast cancer model using multimodal imaging techniques. We demonstrate that PEGylation improves …
Ponik Lab publishes new methods protocol to use endogenous fluorescence to segment intravital images.
May 2022. This novel method demonstrates an intravital imaging workflow pairing collagen second harmonic generation imaging, endogenous fluorescence from the metabolic co-factor NAD(P)H, and fluorescence lifetime imaging microscopy (FLIM) as a means to non-invasively compartmentalize the …
Congrats to Metti Gari! Winner of the 2022 ASMB image contest
“Every Rose has a Fiber” The extracellular matrix in a mouse model of triple negative breast cancer. (Tenascin-C = red, Fibronectin = green, DAPI = blue)
Congratulations to Shelby Fertal on the publication of her review article on the stromal impacts on new therapies for TNBC patients!
In this collaborative review with Drs. Kari Wisinski and Johanna Poterala, we summarize the recent outcomes from clinical trials with new agents for metastatic triple-negative breast cancer, specifically focusing on immunotherapies targeting the PD-1/PD-L1 pathway …